|Bid||6.07 x 1200|
|Ask||6.48 x 800|
|Day's range||6.36 - 6.36|
|52-week range||5.50 - 8.98|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.00|
ORLANDO, Fla., June 13, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration ("FDA") 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System ("ALLY" or "ALLY System"). ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract sur
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
ORLANDO, Fla., May 09, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2022 and provided an update on operational initiatives.